PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

July 30, 2027

Conditions
Hepato Cellular Carcinoma (HCC)
Interventions
DRUG

PD-L1 antibody

1200mg intravenously every 3 weeks

DRUG

Bevacizumab

15mg/kg intravenously every 3 weeks

PROCEDURE

HAIC-FOLFOX

Oxaliplatin 130 mg/m² via hepatic arterial infusion over 3 hours Leucovorin 400 mg/m² via hepatic arterial infusion over 2 hours Fluorouracil 400 mg/m² bolus via hepatic arterial infusion at hour 5, followed by 2400 mg/m² continuous hepatic arterial infusion over 46 hours HAIC treatment repeats every 3 weeks for up to 6 cycles

Trial Locations (1)

610041

RECRUITING

West China Hospital, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER